PROJECT SUMMARY Quantitative dynamic contrast enhancement (DCE) MRI metrics such as tissue perfusion rates, kinetic parameters, extravascular volume, and plasma volume allow characterization of subtle differences in tissue states related to ischemia, vascularity, inflammation, and fibrosis in neurological and cardiovascular diseases, and in cancers such as pancreatic adenocardinoma (PDAC). The reproducible nature of quantitative imaging makes it more suitable for multi-center or longitudinal studies than conventional “qualitative” imaging. Quantitative DCE metrics have been shown to be important for risk assessment, early detection, staging, characterization, and treatment monitoring of PDAC and other diseases. DCE MRI performs imaging before, during, and after injection of a gadolinium (Gd)-based contrast agent. There are several major challenges, especially in moving organs: i) cardiac motion must be dealt with for heart scans, generally by syncing acquisition with an ECG signal, leading to difficulty in arrhythmia patients as well as low imaging efficiency and challenges for whole-heart 3D imaging; ii) respiratory motion must be dealt with, typically by patient breath-holding; iii) safety questions surrounding Gd contrast agents lower the benefit-to-risk ratio in many situations. The objective of this project is to develop low-dose, motion-resolved, quantitative dynamic contrast enhanced (DCE) MRI for PDAC. This will be accomplished by developing and validating the MR multitasking framework for multi-dynamic, highly time-resolved T1 mapping, and correlating MRI measurements to histology in patients undergoing surgical resection. Multitasking designs DCE MRI around the concept of images as functions of multiple time dimensions, each corresponding to a different dynamic process (e.g., motion, T1, DCE). It integrates machine learning, low-rank tensor modeling, compressed sensing, and deep learning to extract reproducible, quantitative measurements from 6D DCE images, even under free-breathing conditions. The resulting technology would be a powerful tool for quantitative MRI tissue characterization in moving organs, and would be promising as a tool for monitoring neoadjuvant therapies prior to pancreatic resection.

PROJECT NARRATIVE This project is to develop and validate low-dose quantitative dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of the pancreas under free-breathing conditions. This will be accomplished by cultivating a new technology, DCE MR Multitasking, which can quantify tissue kinetic and flow parameters even in moving organs. The resulting technology will offer clinicians and investigators a valuable tool to diagnose, monitor, and study pancreatic and other cancers.